Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MD Cream
- Development stage
- Unknown
- Lead developer
- TIMEBIO
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
MD Cream is a topical exosome-based therapeutic candidate being developed by TIMEBIO for the treatment of inflammatory skin diseases, including eczema, psoriasis, and atopic dermatitis. The product utilizes TIMEBIO's proprietary progenitor cell-derived exosome technology (such as ImmunoExo or TEXsome), which is designed to modulate skin inflammation, inhibit inflammatory cytokines, and promote skin barrier repair and tissue regeneration. It is currently in Phase 1 clinical development as a topical formulation.
- Other names
- ImmunoExoTEXsometopical exosome
Beyond the preview
Go deeper on MD Cream.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MD Cream.